000099158 001__ 99158
000099158 005__ 20230519145401.0
000099158 0247_ $$2doi$$a10.1080/2162402X.2020.1853314
000099158 0248_ $$2sideral$$a122630
000099158 037__ $$aART-2021-122630
000099158 041__ $$aeng
000099158 100__ $$aReina-Ortiz, C.
000099158 245__ $$aExpanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients
000099158 260__ $$c2021
000099158 5060_ $$aAccess copy available to the general public$$fUnrestricted
000099158 5203_ $$aIn this study we evaluated the potential of expanded NK cells (eNKs) from two sources combined with the mAbs daratumumab and pembrolizumab to target primary multiple myeloma (MM) cells ex vivo. In order to ascertain the best source of NK cells, we expanded and activated NK cells from peripheral blood (PB) of healthy adult donors and from umbilical cord blood (UCB). The resulting expanded NK (eNK) cells express CD16, necessary for carrying out antibody-dependent cellular cytotoxicity (ADCC). Cytotoxicity assays were performed on bone marrow aspirates of 18 MM patients and 4 patients with monoclonal gammopathy of undetermined significance (MGUS). Expression levels of PD-1 on eNKs and PD-L1 on MM and MGUS cells were also quantified. Results indicate that most eNKs obtained using our expansion protocol express a low percentage of PD-1+ cells. UCB eNKs were highly cytotoxic against MM cells and addition of daratumumab or pembrolizumab did not further increase their cytotoxicity. PB eNKs, while effective against MM cells, were significantly more cytotoxic when combined with daratumumab. In a minority of cases, eNK cells showed a detectable population of PD1+ cells. This correlated with low cytotoxic activity, particularly in UCB eNKs. Addition of pembrolizumab did not restore their activity. Results indicate that UCB eNKs are to be preferentially used against MM in the absence of daratumumab while PB eNKs have significant cytotoxic advantage when combined with this mAb.
000099158 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/SAF2016-76338-R
000099158 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000099158 590__ $$a7.723$$b2021
000099158 592__ $$a2.096$$b2021
000099158 594__ $$a13.3$$b2021
000099158 591__ $$aONCOLOGY$$b48 / 245 = 0.196$$c2021$$dQ1$$eT1
000099158 593__ $$aImmunology and Allergy$$c2021$$dQ1
000099158 591__ $$aIMMUNOLOGY$$b40 / 163 = 0.245$$c2021$$dQ1$$eT1
000099158 593__ $$aImmunology$$c2021$$dQ1
000099158 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000099158 700__ $$aConstantinides, M.
000099158 700__ $$aFayd-Herbe-de-Maudave, A.
000099158 700__ $$aPrésumey, J.
000099158 700__ $$aHernandez, J.
000099158 700__ $$aCartron, G.
000099158 700__ $$aGiraldos, D.
000099158 700__ $$aDíez, R.
000099158 700__ $$aIzquierdo, I.$$uUniversidad de Zaragoza
000099158 700__ $$0(orcid)0000-0001-5068-7355$$aAzaceta, G.$$uUniversidad de Zaragoza
000099158 700__ $$0(orcid)0000-0001-8515-3599$$aPalomera, L.$$uUniversidad de Zaragoza
000099158 700__ $$0(orcid)0000-0002-2315-9079$$aMarzo, I.$$uUniversidad de Zaragoza
000099158 700__ $$0(orcid)0000-0003-2156-8378$$aNaval, J.$$uUniversidad de Zaragoza
000099158 700__ $$0(orcid)0000-0002-5175-8394$$aAnel, A.$$uUniversidad de Zaragoza
000099158 700__ $$aVillalba, M.
000099158 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000099158 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000099158 7102_ $$11002$$2050$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Biología Celular
000099158 773__ $$g10, 1 (2021), 1853314 [11 pp]$$pOncoimmunology$$tOncoImmunology$$x2162-4011
000099158 8564_ $$s700172$$uhttps://zaguan.unizar.es/record/99158/files/texto_completo.pdf$$yVersión publicada
000099158 8564_ $$s1299129$$uhttps://zaguan.unizar.es/record/99158/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000099158 909CO $$ooai:zaguan.unizar.es:99158$$particulos$$pdriver
000099158 951__ $$a2023-05-18-13:39:44
000099158 980__ $$aARTICLE